On this page
CYP3A5
cytochrome P450 family 3 subfamily A member 5
CYP3A5 encodes a cytochrome P450 enzyme that metabolises a wide range of prescription drugs, influencing individual responses to medication. The CYP3A5 gene provides instructions for making an enzyme involved in breaking down various medications and other substances in the body.
CYP3A5 is located on the long (q) arm of chromosome 7, at band 7q22.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 7 in the library →Available at Jeen Health
Clinical tests that include this
Overview
CYP3A5 encodes cytochrome P450 family 3 subfamily A member 5, an enzyme expressed primarily in the liver, kidneys, and intestine. This protein belongs to the cytochrome P450 superfamily, a group of enzymes responsible for metabolising approximately half of all clinically used drugs. CYP3A5 works alongside its closely related counterpart CYP3A4 to process a diverse array of medications, including immunosuppressants, cardiovascular drugs, and certain chemotherapy agents.
Genetic variation in CYP3A5 creates substantial differences in enzyme activity across populations. The most significant variant leads to reduced or absent enzyme production in many individuals, particularly those of European ancestry. This variability has important implications for personalised medicine, as individuals with different CYP3A5 genotypes may require adjusted medication doses to achieve optimal therapeutic outcomes whilst minimising adverse effects. Understanding CYP3A5 status forms part of the growing field of pharmacogenomics, which aims to tailor drug selection and dosing based on an individual's genetic profile.
What the gene does
The CYP3A5 enzyme catalyses oxidative reactions that introduce reactive groups into drug molecules, typically making them more water-soluble and easier for the body to eliminate. This protein uses iron-containing haem as a cofactor to carry out these chemical transformations, accepting electrons from a partner protein called cytochrome P450 reductase. The enzyme sits within the membrane of the endoplasmic reticulum in cells, where it processes lipophilic compounds that can pass through cellular membranes.
CYP3A5 shares approximately 84% amino acid sequence identity with CYP3A4, and the two enzymes demonstrate considerable overlap in the compounds they metabolise. However, CYP3A5 shows higher activity towards certain substrates, including the immunosuppressant tacrolimus and some chemotherapy drugs. The enzyme's substrate-binding pocket accommodates large, structurally diverse molecules, explaining its broad substrate specificity. In individuals who express functional CYP3A5, the enzyme can account for a substantial proportion of total hepatic CYP3A metabolic capacity, particularly for specific drug substrates.
Beyond pharmaceutical compounds, CYP3A5 also participates in the metabolism of endogenous steroids, including testosterone and cortisol. The enzyme's expression levels vary significantly across different tissues, with highest activity typically observed in the liver and kidneys, though substantial individual variation exists depending on genetic factors.
Video: Genetics 101
Chromosome location
The CYP3A5 gene is located on the long arm of chromosome 7 at position 22.1, designated as 7q22.1. This chromosomal region contains a cluster of related CYP3A family genes, including CYP3A4, CYP3A7, and CYP3A43, which likely arose through gene duplication events during evolution. The CYP3A5 gene spans approximately 32 kilobases of genomic DNA and comprises 13 exons that are transcribed and spliced together to form the mature messenger RNA template for protein synthesis.
The clustering of CYP3A genes in this chromosomal region reflects their evolutionary relationship and functional similarities. The proximity of these genes has implications for genetic studies, as variants in regulatory regions may affect expression of multiple CYP3A family members simultaneously.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The CYP3A5 enzyme consists of 502 amino acids that fold into a complex three-dimensional structure characteristic of cytochrome P450 enzymes. The protein contains a buried active site cavity where drug substrates bind and undergo chemical modification. The haem cofactor sits deep within this pocket, coordinated by a conserved cysteine residue that anchors the iron atom. Structural studies of related CYP3A enzymes suggest the substrate-binding cavity is unusually large and flexible, allowing accommodation of diverse molecular structures ranging from small steroids to large macrolide antibiotics.
Key variants
Genetic variation in CYP3A5 profoundly affects enzyme expression and activity. The most clinically significant variant, commonly designated CYP3A5*3, involves a single nucleotide change in intron 3 that creates a cryptic splice site. This alteration causes premature termination of the protein, resulting in little to no functional enzyme. Individuals carrying two copies of this variant are classified as CYP3A5 non-expressers and rely primarily on CYP3A4 for metabolism of CYP3A substrates.
The frequency of CYP3A5 expression alleles varies dramatically across ancestral populations. Functional CYP3A5 expression is relatively common in individuals of African ancestry, with approximately 40-60% retaining at least one active copy of the gene. In contrast, the majority of individuals with European or East Asian ancestry carry two copies of non-functional variants and do not produce meaningful amounts of CYP3A5 enzyme. Additional variants exist that affect enzyme function to varying degrees, though the CYP3A5*3 allele accounts for most functional variability in clinical practice. This population-level diversity reflects different evolutionary selective pressures and historical migration patterns.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
CYP3A5 genetic variation does not cause inherited disease in the traditional sense. Instead, different genotypes influence how individuals respond to medications that are metabolised by this enzyme. Individuals who express functional CYP3A5 typically clear certain drugs more rapidly from their bodies, potentially requiring higher doses to achieve therapeutic drug levels. Conversely, non-expressers may experience higher drug concentrations from standard doses, increasing both therapeutic effects and risk of adverse reactions.
The most extensively studied clinical scenario involves tacrolimus, an immunosuppressant used to prevent organ rejection after transplantation. CYP3A5 expressers generally require substantially higher tacrolimus doses to reach target blood concentrations compared to non-expressers. Similar effects have been documented for other medications including certain calcium channel blockers, HIV protease inhibitors, and chemotherapy agents. Understanding these pharmacogenomic relationships allows clinicians to personalise medication dosing, though implementation varies across healthcare settings.
No disease links recorded for this gene in our reference set.
UK clinical status
Diet & lifestyle considerations
Research into dietary factors affecting CYP3A5 activity has identified several compounds that may influence enzyme function, though evidence remains limited compared to the more extensively studied CYP3A4 enzyme. Grapefruit juice contains furanocoumarins that can inhibit intestinal CYP3A enzymes, potentially affecting drug metabolism in CYP3A5 expressers, though the magnitude of this interaction appears smaller than effects on CYP3A4. Some studies suggest that cruciferous vegetables may modestly induce CYP3A expression through activation of certain cellular signalling pathways.
St John's wort, a herbal supplement sometimes used for mood support, can substantially increase CYP3A enzyme activity through activation of the pregnane X receptor. This induction may reduce blood levels of medications metabolised by CYP3A5 in expressers. However, the clinical significance of these dietary and herbal interactions varies considerably between individuals and depends on baseline CYP3A5 expression status, making general dietary recommendations difficult to formulate. Individuals taking medications with narrow therapeutic windows should discuss potential food-drug interactions with their healthcare provider.
Supplement considerations
No dietary supplements have been conclusively shown to compensate for differences in CYP3A5 activity or to prevent adverse drug reactions related to CYP3A5 genetic variants. Some complementary medicine practitioners suggest various herbal preparations to support liver function, but robust clinical evidence for these interventions affecting CYP3A5-mediated drug metabolism is lacking.
Certain supplements may actually complicate medication management in individuals whose CYP3A5 status affects drug response. For example, supplements containing St John's wort can unpredictably alter enzyme activity levels, potentially leading to subtherapeutic medication concentrations. Anyone taking prescription medications metabolised by CYP3A enzymes should consult their healthcare provider before starting any new supplements, as even seemingly innocuous products may interact with drug metabolism pathways. Pharmacogenomic testing to determine CYP3A5 status, when combined with clinical expertise, remains the most evidence-based approach to personalising medication therapy.
Frequently asked questions
What does it mean to be a CYP3A5 expresser versus non-expresser?
CYP3A5 expressers carry at least one functional copy of the gene and produce active enzyme, whilst non-expressers have genetic variants that prevent enzyme production. Expressers typically metabolise certain medications more rapidly and may require higher doses, whilst non-expressers rely primarily on the related CYP3A4 enzyme.
Should I have CYP3A5 genetic testing?
CYP3A5 testing may be valuable if you are starting medications with narrow therapeutic windows that are significantly metabolised by this enzyme, such as tacrolimus after organ transplantation. The decision to pursue pharmacogenomic testing should be made in consultation with your healthcare provider based on your specific clinical circumstances.
Can CYP3A5 variants cause disease?
CYP3A5 genetic variants do not cause inherited diseases. Instead, they influence how quickly your body processes certain medications, which can affect drug efficacy and risk of side effects. These variants are common normal variations in the population rather than pathogenic mutations.
Do CYP3A5 variants affect all medications?
No, CYP3A5 variants only affect drugs that are substantially metabolised by this specific enzyme. Many medications are processed by different enzymes or metabolic pathways and would not be influenced by CYP3A5 genetic status. A healthcare provider or pharmacist can identify which medications are affected.
How common is functional CYP3A5 expression?
Functional CYP3A5 expression varies by ancestry, being relatively common in individuals of African descent but less frequent in European and East Asian populations. This variation reflects evolutionary selection and historical migration patterns rather than any health advantage or disadvantage.